Skip to main content
  • Saved

A 32-year-old female, Amber, is a non-smoker with a history of familial hypercholesterolemia (FH). Her father underwent a coronary artery bypass grafting (CABG) at the age of 38 and has hypercholesterolemia. Amber was first diagnosed with the disease at 27. She developed angina while breastfeeding her first child. Cardiac catheterization revealed the presence of three-vessel disease prompting her to undergo a coronary artery bypass of her own at that time.

Amber presents to her physician today because she is interested in becoming pregnant once again. She was treated with rosuvastatin and ezetimibe daily at her last routine follow-up appointment. She declined inhibitors like kexin type 9 and proprotein convertase subtilisin.

Given what is known about the effects of Amber's medications on the unborn fetus, what is your treatment recommendation and why?

Sign In or Register Today to Access This Content